Special Issue "New Biomarkers for Diagnosis and Therapy in Civilization Diseases"
Deadline for manuscript submissions: 10 November 2023 | Viewed by 3236
Interests: autoimmunity; cancer; monoclonal gammopathy; minimal residual disease; biomarkers; other biological fluid; new technologies
Special Issues, Collections and Topics in MDPI journals
Biomarkers have been used for the clinical diagnosis of multiple diseases for many years. Measurement with automated technology in the era of precision medicine shows the vastly important evolution of biomarkers in biomedicine. The study of cell surface markers has become an indispensable tool for diagnosing hematological malignancies and monitoring minimal residual diseases. The increase of average age highlights neurodegenerative pathologies and the presence of inflammation, representing new challenges in therapies and biomarker research fields. The applications of gene chips and microarray technology to simultaneously assess multiple molecular markers with Next-Generation Sequencing (NGS), used to sequence entire genomes or constrained to specific areas of interest, are simple and cheaper. Bioluminex, Planar Array Assay and other new assays open new scenarios for autoimmune diseases.
Biomarkers provide personalized prediction of relapse risk and can potentially reduce unnecessary adjuvant chemotherapy. More biomarkers will replace time-consuming traditional endpoints, accelerating the translation of novel agents from bench to bedside, improving patient outcome.
The use of different matrixes, such as as saliva, cerebrospinal fluid, tears and synovial fluids, will be evaluated.
The aim of this Special Issue is to invite original research articles or reviews presenting and discussing the advancement of biomarkers research and innovative therapies involved in cancer, autoimmune diseases and neurodegenerative diseases, with a special interest in the use of biological drugs in these pathologies and advances in genetics, in innovative assays and in molecular diagnostics.
Dr. Umberto Basile
Prof. Dr. Silvia Angeletti
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- long COVID
- gender and inflammation
- new biomarkers in autoimmunity and therapies
- biomarkers of minimal residual disease
- microbiota and autoimmunity
- aging and inflammation
- neurodegenerative disease molecular aspects
- new technologies in precision medicine
- biomarkers and therapy of autoinflammatory diseases